Log in

NASDAQ:MESOMesoblast Stock Price, Forecast & News

$12.04
+0.46 (+3.97 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.77
Now: $12.04
$12.10
50-Day Range
$10.91
MA: $12.53
$13.94
52-Week Range
$3.12
Now: $12.04
$20.57
Volume315,968 shs
Average Volume481,834 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.51
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Read More
Mesoblast logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MESO
Previous SymbolOTCMKTS:MBLTY
CUSIPN/A
CIKN/A
Phone61-3-9639-6036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.72 million
Book Value$4.82 per share

Profitability

Net Income$-89,800,000.00
Net Margins-197.65%

Miscellaneous

Employees81
Market Cap$1.40 billion
Next Earnings Date9/3/2020 (Estimated)
OptionableOptionable

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

How has Mesoblast's stock been impacted by COVID-19 (Coronavirus)?

Mesoblast's stock was trading at $6.0250 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MESO shares have increased by 99.8% and is now trading at $12.04. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mesoblast?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mesoblast.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Mesoblast.

How were Mesoblast's earnings last quarter?

Mesoblast limited (NASDAQ:MESO) posted its quarterly earnings results on Wednesday, May, 27th. The company reported ($0.14) EPS for the quarter, hitting analysts' consensus estimates of ($0.14). The company earned $12.20 million during the quarter, compared to analyst estimates of $9.38 million. Mesoblast had a negative net margin of 197.65% and a negative return on equity of 13.59%. View Mesoblast's earnings history.

What price target have analysts set for MESO?

7 Wall Street analysts have issued 1 year target prices for Mesoblast's stock. Their forecasts range from $6.00 to $23.00. On average, they anticipate Mesoblast's stock price to reach $15.04 in the next twelve months. This suggests a possible upside of 24.9% from the stock's current price. View analysts' price targets for Mesoblast.

Has Mesoblast been receiving favorable news coverage?

News headlines about MESO stock have been trending negative on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mesoblast earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the immediate future. View the latest news about Mesoblast.

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Exelixis (EXEL), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), TherapeuticsMD (TXMD), AbbVie (ABBV), Sangamo Therapeutics (SGMO) and Aduro BioTech (ADRO).

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 71)

When did Mesoblast IPO?

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $12.04.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $1.40 billion and generates $16.72 million in revenue each year. The company earns $-89,800,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Mesoblast employs 81 workers across the globe.

What is Mesoblast's official website?

The official website for Mesoblast is www.mesoblast.com.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.